

WEST Search History

DATE: Monday, February 06, 2006

Hide?	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
		<i>DB=PGPB,USPT,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>	
<input type="checkbox"/>	L23	L21 and (dr1p\$4 or dr5p\$4)	1
<input type="checkbox"/>	L22	L21 and phosphorylas\$4	7
<input type="checkbox"/>	L21	L1 and (Tischer or Ihlenfeldt or Barzu or Sakamoto or Pistotnik or Marliere or Pochet).in.	42
<input type="checkbox"/>	L20	L19 and (dr1p\$4 or dr5p\$4)	4
<input type="checkbox"/>	L19	L18 and vitro\$4	1108
<input type="checkbox"/>	L18	L17 and (synthes\$4 or produc\$4)	1262
<input type="checkbox"/>	L17	L16 and phosphat\$4	1265
<input type="checkbox"/>	L16	L15 and (mutas\$4 or aldolas\$4 or transferas\$4)	1285
<input type="checkbox"/>	L15	L14 and (purine\$4 or pyrimidine\$4)	2321
<input type="checkbox"/>	L14	L13 and phosphorylas\$4	2983
<input type="checkbox"/>	L13	deoxyribonucleosid\$4 or nucleosid\$4	35628
<input type="checkbox"/>	L12	L11 and (dr1p\$ or r1p\$4)	5
<input type="checkbox"/>	L11	L10 and (aldolas\$4 or mutas\$4 or transferas\$4)	1325
<input type="checkbox"/>	L10	L9 and phosphorylas\$4	2389
<input type="checkbox"/>	L9	l1 and (purin\$4 or pyrimidin\$4)	17007
<input type="checkbox"/>	L8	L7 and transferas?	76
<input type="checkbox"/>	L7	L6 and (mutase\$4 or aldolas\$4)	87
<input type="checkbox"/>	L6	L5 same (produc\$4 or synthe\$4)	679
<input type="checkbox"/>	L5	L4 same (purin\$4 or pyrimidin\$4)	1701
<input type="checkbox"/>	L4	L1 same phosphorylas\$4	2106
<input type="checkbox"/>	L3	L2 and purine\$4	2185
<input type="checkbox"/>	L2	L1 and phosphorylas\$4	3065
<input type="checkbox"/>	L1	deoxynucleosid\$4 or nucleosid\$4	36122

END OF SEARCH HISTORY

=> d his full

(FILE 'HOME' ENTERED AT 12:40:16 ON 06 FEB 2006)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 12:40:29 ON 06 FEB 2006
SEA NUCLEOSIDE? OR DEOXINUCLEOSID?

31680 FILE ADISCTI
402 FILE ADISINSIGHT
587 FILE ADISNEWS
888 FILE AGRICOLA
987 FILE ANABSTR
7 FILE ANTE
18 FILE AQUALINE
273 FILE AQUASCI
1434 FILE BIOENG
34089 FILE BIOSIS
2646 FILE BIOTECHABS
2646 FILE BIOTECHDS
8222 FILE BIOTECHNO
2517 FILE CABA
56448 FILE CAPLUS
357 FILE CEABA-VTB
477 FILE CIN
973 FILE CONFSCI
40 FILE CROPB
113 FILE CROPU
14692 FILE DDFB
9472 FILE DDFU
42966 FILE DGENE
2095 FILE DISSABS
14692 FILE DRUGB
10919 FILE DRUGU
236 FILE EMBAL
27403 FILE EMBASE
8796 FILE ESBIODBASE
566 FILE FEDRIP
172 FILE FROSTI
401 FILE FSTA
28121 FILE GENBANK
53 FILE HEALSAFE
4539 FILE IFIPAT
763 FILE IMSDRUGNEWS
8 FILE IMSPRODUCT
345 FILE IMSRESEARCH
12585 FILE JICST-EPLUS
6 FILE KOSMET
9317 FILE LIFESCI
36165 FILE MEDLINE
259 FILE NIOSHTIC
432 FILE NTIS
2 FILE NUTRACEUT
56 FILE OCEAN
27779 FILE PASCAL
11 FILE PCTGEN
248 FILE PHAR
347 FILE PHARMAML
5 FILE PHIC
820 FILE PHIN
3697 FILE PROMT
1424 FILE PROUSDDR
1 FILE PS
1 FILE RDISCLOSURE
32836 FILE SCISEARCH
235 FILE SYNTHLINE

24665 FILE TOXCENTER
 24317 FILE USPATFULL
 2059 FILE USPAT2
 147 FILE VETB
 54 FILE VETU
 29 FILE WATER
 5492 FILE WPIDS
 30 FILE WPIFV
 5492 FILE WPINDEX
 712 FILE IPA
 151 FILE NAPRALERT
 2186 FILE NLDB

L1 QUE NUCLEOSIDE? OR DEOXINUCLEOSID?

D RANK

FILE 'CAPLUS, MEDLINE, BIOSIS, SCISEARCH, ADISCTI, GENBANK, PASCAL, EMBASE, TOXCENTER, USPATFULL' ENTERED AT 12:43:10 ON 06 FEB 2006

L2 323503 SEA NUCLEOSIDE? OR DEOXINUCLEOSID?
 L3 15679 SEA L2 (S) PHOSPHORYLAS?
 L4 1775 SEA L3 (S)(SYNTH?)
 L5 2714 SEA L3(S)(PRODUC? OR SYNTH?)
 L6 3 SEA L5 AND PHOSPHOPENTOSE?
 L7 430 SEA L5 AND ALDOLAS?
 L8 314 SEA L7 AND MUTASE?
 L9 2311 SEA L5 AND (PURIN? OR PYRIMIDIN?)
 L10 449 SEA L9 AND (MUTAS? OR ALDOLAS? OR PHOSPHOPENTOS?)
 L11 391 SEA L10 AND TRANSFERAS?
 L12 391 DUP REM L11 (0 DUPLICATES REMOVED)
 D TI L12 1-100
 D TI L12 101-200
 D TI L12 201-300
 D TI L12 301-391
 D TI L6 1-3
 L13 338433 SEA DEOXYRIBONUCLEOSI? OR NUCLEOSID?
 L14 15679 SEA L3 AND PHOSPHORYLAS?
 L15 18246 SEA L13 AND PHOSPHORYLAS?
 L16 3148 SEA L15 AND (MUTAS? OR TRANSFERAS? OR ALDOLAS?)
 L17 2309 SEA L16 AND PHOSPHAT?
 L18 1243 SEA L17 AND THYMIDIN?
 L19 1059 SEA L18 AND (PURIN? OR PYRIMIDINE?)
 L20 1014 SEA L19 AND (SYNTHE? OR PRODUCT?)
 L21 67 SEA L20 AND DR1P? OR DR5P?
 L22 4 SEA L20 AND (DR1P? OR DR5P?)
 D TI L22 1-4

> file medline biosis caplus

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		0.21	0.21

FILE 'MEDLINE' ENTERED AT 18:22:39 ON 06 FEB 2006

FILE 'BIOSIS' ENTERED AT 18:22:39 ON 06 FEB 2006

Copyright (c) 2006 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 18:22:39 ON 06 FEB 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s inorganic(s)phosphat?(s)remov?

L1 192 INORGANIC(S) PHOSPHAT?(S) REMOV?

=> s l1(s)pyrophosphat?

L2 8 L1(S) PYROPHOSPHAT?

=> s inorganic(s)phosphat?(s)precipit?

L3 160 INORGANIC(S) PHOSPHAT?(S) PRECIPIT?

=> s l3(s)pyrophosphat?
L4 1 L3(S) PYROPHOSPHAT?

=> d ti l4

L4 ANSWER 1 OF 1 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
TI EFFECTS OF THE ADDITION OF CALCIUM ON THE COLLOIDAL STABILITY OF SOYMILK.

=> s inorganic(s)phosphat?(s)phosphofructosekinas?
L5 0 INORGANIC(S) PHOSPHAT?(S) PHOSPHOFRUCTOSEKINAS?

=> s inorganic(s)phosphat?(s)phosphofructokinas?
L6 57 INORGANIC(S) PHOSPHAT?(S) PHOSPHOFRUCTOKINAS?

=> d ti l6 1-57

=> index bioscience medicine
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 10:33:28 ON 08 FEB 2006

73 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s inorgan?(s)phosphat?(s)pyrophosphat?

74 FILE AGRICOLA
17 FILE ANABSTR
1 FILE ANTE
6 FILE AQUALINE
18 FILE AQUASCI
27 FILE BIOENG
296 FILE BIOSIS
68 FILE BIOTECHABS
68 FILE BIOTECHDS
155 FILE BIOTECHNO
193 FILE CABA
179 FILE CAPLUS
5 FILE CEABA-VTB
4 FILE CONFSCI

18 FILES SEARCHED...

4 FILE CROPU
25 FILE DDFB
6 FILE DDFU
133 FILE DGENE
38 FILE DISSABS
25 FILE DRUGB
13 FILE DRUGU
3 FILE EMBAL
194 FILE EMBASE
172 FILE ESBIODASE
12* FILE FEDRIP
2 FILE FOMAD

33 FILES SEARCHED...

4 FILE FROSTI
41 FILE FSTA
337 FILE GENBANK
1 FILE HEALSAFE
194 FILE IFIPAT

20 FILE JICST-EPLUS
 1 FILE KOSMET
 176 FILE LIFESCI
 311 FILE MEDLINE
 9 FILE NIOSHTIC
 8 FILE NTIS
 4 FILE OCEAN
 135 FILE PASCAL
 14 FILE PROMT
 13 FILE RDISCLOSURE
 59 FILES SEARCHED...
 214 FILE SCISEARCH
 37 FILE TOXCENTER
 4584 FILE USPATFULL
 407 FILE USPAT2
 9 FILE WATER
 474 FILE WPIDS
 1 FILE WPIFV
 474 FILE WPINDEX
 2 FILE IPA
 1 FILE NAPRALERT
 6 FILE NLDB

52 FILES HAVE ONE OR MORE ANSWERS, 73 FILES SEARCHED IN STNINDEX

L1 QUE INORGAN?(S) PHOSPHAT?(S) PYROPHOSPHAT?

=> d rank

F1 4584 USPATFULL
 F2 474 WPIDS
 F3 474 WPINDEX
 F4 407 USPAT2
 F5 337 GENBANK
 F6 311 MEDLINE
 F7 296 BIOSIS
 F8 214 SCISEARCH
 F9 194 EMBASE
 F10 194 IFIPAT
 F11 193 CABA
 F12 179 CAPLUS
 F13 176 LIFESCI
 F14 172 ESBIOBASE
 F15 155 BIOTECHNO
 F16 135 PASCAL
 F17 133 DGENE
 F18 74 AGRICOLA
 F19 68 BIOTECHABS
 F20 68 BIOTECHDS
 F21 41 FSTA
 F22 38 DISSABS
 F23 37 TOXCENTER
 F24 27 BIOENG
 F25 25 DDFB
 F26 25 DRUGB
 F27 20 JICST-EPLUS
 F28 18 AQUASCI
 F29 17 ANABSTR
 F30 14 PROMT
 F31 13 DRUGU
 F32 13 RDISCLOSURE
 F33 12* FEDRIP
 F34 9 NIOSHTIC
 F35 9 WATER
 F36 8 NTIS
 F37 6 AQUALINE
 F38 6 DDFU
 F39 6 NLDB
 F40 5 CEABA-VTB

F41 4 CONFSCI
 F42 4 CROPU
 F43 4 FROSTI
 F44 4 OCEAN
 F45 3 EMBAL
 F46 2 FOMAD
 F47 2 IPA
 F48 1 ANTE
 F49 1 HEALSAFE
 F50 1 KOSMET
 F51 1 WPIFV
 F52 1 NAPRALERT

=> file f1-f4,f6-f11

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		2.44	2.65

FILE 'USPATFULL' ENTERED AT 10:35:48 ON 08 FEB 2006
 CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 10:35:48 ON 08 FEB 2006
 COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'USPAT2' ENTERED AT 10:35:48 ON 08 FEB 2006
 CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 10:35:48 ON 08 FEB 2006

FILE 'BIOSIS' ENTERED AT 10:35:48 ON 08 FEB 2006
 Copyright (c) 2006 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 10:35:48 ON 08 FEB 2006
 Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 10:35:48 ON 08 FEB 2006
 Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'IFIPAT' ENTERED AT 10:35:48 ON 08 FEB 2006
 COPYRIGHT (C) 2006 IFI CLAIMS(R) Patent Services (IFI)

FILE 'CABA' ENTERED AT 10:35:48 ON 08 FEB 2006
 COPYRIGHT (C) 2006 CAB INTERNATIONAL (CABI)

=> s inorgan?(s)phosphat?(s)pyrophosphat?
 L2 6867 INORGAN?(S) PHOSPHAT?(S) PYROPHOSPHAT?

=> s l2 (s)(conver? or remov? or complex? or precipit?)
 2 FILES SEARCHED...
 L3 819 L2 (S)(CONVER? OR REMOV? OR COMPLEX? OR PRECIPIT?)

=> s l3(s)enzym?
 L4 183 L3(S) ENZYM?

=> dup rem l4
 PROCESSING COMPLETED FOR L4
 L5 164 DUP REM L4 (19 DUPLICATES REMOVED)

=> s l3(s)phosphofructokinas?
 L6 24 L3(S) PHOSPHOFRUCTOKINAS?

=> dup rem l6
 PROCESSING COMPLETED FOR L6
 L7 23 DUP REM L6 (1 DUPLICATE REMOVED)

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal652dmr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6 DEC 14 CA/Caplus to be enhanced with updated IPC codes
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/Caplus with the
IPC reform
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 13 JAN 30 Saved answer limit increased
NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency
added to TULSA

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:40:16 ON 06 FEB 2006

=> index bioscience medicine

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,
CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,
DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 12:40:29 ON 06 FEB 2006

73 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s nucleoside? or deoxinucleosid?

31680	FILE ADISCTI
402	FILE ADISINSIGHT
587	FILE ADISNEWS
888	FILE AGRICOLA
987	FILE ANABSTR
7	FILE ANTE
18	FILE AQUALINE
273	FILE AQUASCI
1434	FILE BIOENG
34089	FILE BIOSIS
2646	FILE BIOTECHABS
2646	FILE BIOTECHDS
8222	FILE BIOTECHNO
2517	FILE CABA
56448	FILE CAPLUS
357	FILE CEABA-VTB
477	FILE CIN
973	FILE CONFSCI
40	FILE CROPB
113	FILE CROPU
14692	FILE DDFB
9472	FILE DDFU
42966	FILE DGENE
2095	FILE DISSABS
14692	FILE DRUGB
10919	FILE DRUGU
236	FILE EMBAL
27403	FILE EMBASE
8796	FILE ESBIODBASE
566	FILE FEDRIP
172	FILE FROSTI
401	FILE FSTA
28121	FILE GENBANK
53	FILE HEALSAFE
4539	FILE IFIPAT
763	FILE IMSDRUGNEWS
8	FILE IMSPRODUCT
345	FILE IMSRESEARCH
41 FILES SEARCHED...	
12585	FILE JICST-EPLUS
6	FILE KOSMET
9317	FILE LIFESCI
36165	FILE MEDLINE
259	FILE NIOSHTIC
432	FILE NTIS
2	FILE NUTRACEUT
56	FILE OCEAN
27779	FILE PASCAL
11	FILE PCTGEN
248	FILE PHAR
347	FILE PHARMAML
5	FILE PHIC
820	FILE PHIN

3697	FILE PROMT
1424	FILE PROUSDDR
1	FILE PS
1	FILE RDISCLOSURE
32836	FILE SCISEARCH
235	FILE SYNTHLINE
24665	FILE TOXCENTER
24317	FILE USPATFULL
2059	FILE USPAT2
147	FILE VETB
54	FILE VETU
29	FILE WATER
5492	FILE WPIDS
30	FILE WPIFV
5492	FILE WPINDEX
712	FILE IPA
151	FILE NAPRALERT
2186	FILE NLDB

70 FILES HAVE ONE OR MORE ANSWERS, 73 FILES SEARCHED IN STNINDEX

L1 QUE NUCLEOSIDE? OR DEOXINUCLEOSID?

=> d rank

F1	56448	CAPLUS
F2	42966	DGENE
F3	36165	MEDLINE
F4	34089	BIOSIS
F5	32836	SCISEARCH
F6	31680	ADISCTI
F7	28121	GENBANK
F8	27779	PASCAL
F9	27403	EMBASE
F10	24665	TOXCENTER
F11	24317	USPATFULL
F12	14692	DDFB
F13	14692	DRUGB
F14	12585	JICST-EPLUS
F15	10919	DRUGU
F16	9472	DDFU
F17	9317	LIFESCI
F18	8796	ESBIOBASE
F19	8222	BIOTECHNO
F20	5492	WPIDS
F21	5492	WPINDEX
F22	4539	IFIPAT
F23	3697	PROMT
F24	2646	BIOTECHABS
F25	2646	BIOTECHDS
F26	2517	CABA
F27	2186	NLDB
F28	2095	DISSABS
F29	2059	USPAT2
F30	1434	BIOENG
F31	1424	PROUSDDR
F32	987	ANABSTR
F33	973	CONFSCI
F34	888	AGRICOLA
F35	820	PHIN
F36	763	IMSDRUGNEWS
F37	712	IPA
F38	587	ADISNEWS
F39	566	FEDRIP
F40	477	CIN
F41	432	NTIS

F42	402	ADISINSIGHT
F43	401	FSTA
F44	357	CEABA-VTB
F45	347	PHARMAML
F46	345	IMSRESEARCH
F47	273	AQUASCI
F48	259	NIOSHTIC
F49	248	PHAR
F50	236	EMBAL
F51	235	SYNTHLINE
F52	172	FROSTI
F53	151	NAPRALERT
F54	147	VETB
F55	113	CROPU
F56	56	OCEAN
F57	54	VETU
F58	53	HEALSAFE
F59	40	CROPB
F60	30	WPIFV
F61	29	WATER
F62	18	AQUALINE
F63	11	PCTGEN
F64	8	IMSPRODUCT
F65	7	ANTE
F66	6	KOSMET
F67	5	PHIC
F68	2	NUTRACEUT
F69	1	PS
F70	1	RDISCLOSURE

=> file f1, f3-f11
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
3.05	3.26

FILE 'CAPLUS' ENTERED AT 12:43:10 ON 06 FEB 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:43:10 ON 06 FEB 2006

FILE 'BIOSIS' ENTERED AT 12:43:10 ON 06 FEB 2006
 Copyright (c) 2006 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 12:43:10 ON 06 FEB 2006
 Copyright (c) 2006 The Thomson Corporation

FILE 'ADISCTI' ENTERED AT 12:43:10 ON 06 FEB 2006
 COPYRIGHT (C) 2006 Adis Data Information BV

FILE 'GENBANK' ENTERED AT 12:43:10 ON 06 FEB 2006

FILE 'PASCAL' ENTERED AT 12:43:10 ON 06 FEB 2006
 Any reproduction or dissemination in part or in full,
 by means of any process and on any support whatsoever
 is prohibited without the prior written agreement of INIST-CNRS.
 COPYRIGHT (C) 2006 INIST-CNRS. All rights reserved.

FILE 'EMBASE' ENTERED AT 12:43:10 ON 06 FEB 2006
 Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'TOXCENTER' ENTERED AT 12:43:10 ON 06 FEB 2006
 COPYRIGHT (C) 2006 ACS

FILE 'USPATFULL' ENTERED AT 12:43:10 ON 06 FEB 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s nucleoside? or deoxinucleosid?

L2 323503 NUCLEOSIDE? OR DEOXINUCLEOSID?

=> s l2 (s)phosphorylas?

L3 15679 L2 (S) PHOSPHORYLAS?

=> s l3 (s)(synthe?)

L4 1775 L3 (S) (SYNTHE?)

=> s l3(s)(produc? or synthe?)

7 FILES SEARCHED...

L5 2714 L3(S) (PRODUC? OR SYNTHE?)

=> s l5 and phosphopentose?

L6 3 L5 AND PHOSPHOPENTOSE?

=> s l5 and aldolas?

L7 430 L5 AND ALDOLAS?

=> s l7 and mutase?

L8 314 L7 AND MUTASE?

=> s l5 and (purin? or pyrimidin?)

L9 2311 L5 AND (PURIN? OR PYRIMIDIN?)

=> s l9 and (mutas? or aldolas? or phosphopentos?)

L10 449 L9 AND (MUTAS? OR ALDOLAS? OR PHOSPHOPENTOS?)

=> s l10 and transferas?

L11 391 L10 AND TRANSFERAS?

=> dup rem l11

DUPLICATE IS NOT AVAILABLE IN 'GENBANK'.

ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

PROCESSING COMPLETED FOR L11

L12 391 DUP REM L11 (0 DUPLICATES REMOVED)

=> d ti l12 1-100

L12 ANSWER 1 OF 391 USPATFULL on STN

TI Use of interfering RNA in the production of transgenic animals

L12 ANSWER 2 OF 391 USPATFULL on STN

TI Methods for identifying small molecules that modulate premature translation termination and nonsense mrna decay

L12 ANSWER 3 OF 391 USPATFULL on STN

TI Methods and products based on oligomerization of stress proteins

L12 ANSWER 4 OF 391 USPATFULL on STN

TI Signatures of ER status in breast cancer

L12 ANSWER 5 OF 391 USPATFULL on STN

TI Polynucleotides and polypeptides, materials incorporating them and methods for using them

L12 ANSWER 6 OF 391 USPATFULL on STN

TI Methods and apparatus for gel-free qualitative and quantitative proteome analysis, and uses therefore

L12 ANSWER 7 OF 391 USPATFULL on STN

L22 ANSWER 4 OF 4 USPATFULL on STN

TI Methods for identifying drug targets based on genomic sequence data

=> d his full

(FILE 'HOME' ENTERED AT 12:40:16 ON 06 FEB 2006)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 12:40:29 ON 06 FEB 2006
SEA NUCLEOSIDE? OR DEOXINUCLEOSID?

31680 FILE ADISCTI
402 FILE ADISINSIGHT
587 FILE ADISNEWS
888 FILE AGRICOLA
987 FILE ANABSTR
7 FILE ANTE
18 FILE AQUALINE
273 FILE AQUASCI
1434 FILE BIOENG
34089 FILE BIOSIS
2646 FILE BIOTECHABS
2646 FILE BIOTECHDS
8222 FILE BIOTECHNO
2517 FILE CABA
56448 FILE CAPLUS
357 FILE CEABA-VTB
477 FILE CIN
973 FILE CONFSCI
40 FILE CROPB
113 FILE CROPU
14692 FILE DDFB
9472 FILE DDFU
42966 FILE DGENE
2095 FILE DISSABS
14692 FILE DRUGB
10919 FILE DRUGU
236 FILE EMBAL
27403 FILE EMBASE
8796 FILE ESBIODASE
566 FILE FEDRIP
172 FILE FROSTI
401 FILE FSTA
28121 FILE GENBANK
53 FILE HEALSAFE
4539 FILE IFIPAT
763 FILE IMSDRUGNEWS
8 FILE IMSPRODUCT
345 FILE IMSRESEARCH
12585 FILE JICST-EPLUS
6 FILE KOSMET
9317 FILE LIFESCI
36165 FILE MEDLINE
259 FILE NIOSHTIC
432 FILE NTIS
2 FILE NUTRACEUT
56 FILE OCEAN
27779 FILE PASCAL
11 FILE PCTGEN
248 FILE PHAR
347 FILE PHARMAML
5 FILE PHIC

820 FILE PHIN
 3697 FILE PROMT
 1424 FILE PROUSDDR
 1 FILE PS
 1 FILE RDISCLOSURE
 32836 FILE SCISEARCH
 235 FILE SYNTHLINE
 24665 FILE TOXCENTER
 24317 FILE USPATFULL
 2059 FILE USPAT2
 147 FILE VETB
 54 FILE VETU
 29 FILE WATER
 5492 FILE WPIDS
 30 FILE WPIFV
 5492 FILE WPINDEX
 712 FILE IPA
 151 FILE NAPRALERT
 2186 FILE NLDB

L1 QUE NUCLEOSIDE? OR DEOXINUCLEOSID?

 D RANK

FILE 'CAPLUS, MEDLINE, BIOSIS, SCISEARCH, ADISCTI, GENBANK, PASCAL, EMBASE, TOXCENTER, USPATFULL' ENTERED AT 12:43:10 ON 06 FEB 2006

L2 323503 SEA NUCLEOSIDE? OR DEOXINUCLEOSID?
 L3 15679 SEA L2 (S) PHOSPHORYLAS?
 L4 1775 SEA L3 (S) (SYNTH?)
 L5 2714 SEA L3 (S) (PRODUC? OR SYNTH?)
 L6 3 SEA L5 AND PHOSPHOPENTOSE?
 L7 430 SEA L5 AND ALDOLAS?
 L8 314 SEA L7 AND MUTASE?
 L9 2311 SEA L5 AND (PURIN? OR PYRIMIDIN?)
 L10 449 SEA L9 AND (MUTAS? OR ALDOLAS? OR PHOSPHOPENTOS?)
 L11 391 SEA L10 AND TRANSFERAS?
 L12 391 DUP REM L11 (0 DUPLICATES REMOVED)
 D TI L12 1-100
 D TI L12 101-200
 D TI L12 201-300
 D TI L12 301-391
 D TI L6 1-3
 L13 338433 SEA DEOXYRIBONUCLEOSI? OR NUCLEOSID?
 L14 15679 SEA L3 AND PHOSPHORYLAS?
 L15 18246 SEA L13 AND PHOSPHORYLAS?
 L16 3148 SEA L15 AND (MUTAS? OR TRANSFERAS? OR ALDOLAS?)
 L17 2309 SEA L16 AND PHOSPHAT?
 L18 1243 SEA L17 AND THYMIDIN?
 L19 1059 SEA L18 AND (PURIN? OR PYRIMIDINE?)
 L20 1014 SEA L19 AND (SYNTHES? OR PRODUCT?)
 L21 67 SEA L20 AND DR1P? OR DR5P?
 L22 4 SEA L20 AND (DR1P? OR DR5P?)
 D TI L22 1-4

FILE HOME

FILE STNINDEX

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE
IN THE BASIC INDEX (/BI) FIELD <<<

FILE EMBASE

FILE COVERS 1974 TO 2 Feb 2006 (20060202/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

FILE TOXCENTER

FILE COVERS 1907 TO 31 Jan 2006 (20060131/ED)

This file contains CAS Registry Numbers for easy and accurate substance
identification.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TOXCENTER has been enhanced with new files segments and search fields.
See HELP CONTENT for more information.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the
MeSH 2006 vocabulary.

See <http://www.nlm.nih.gov/mesh/>

http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html

http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

for a description of changes.

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 2 Feb 2006 (20060202/PD)

FILE LAST UPDATED: 2 Feb 2006 (20060202/ED)

HIGHEST GRANTED PATENT NUMBER: US6993790

HIGHEST APPLICATION PUBLICATION NUMBER: US2006026727

CA INDEXING IS CURRENT THROUGH 2 Feb 2006 (20060202/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 2 Feb 2006 (20060202/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2005

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2005

=> log h

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

486.26

489.52

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 13:17:16 ON 06 FEB 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal652dmr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
 NEWS 2 "Ask CAS" for self-help around the clock
 NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
 NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
 NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
 NEWS 6 DEC 14 CA/CAPLUS to be enhanced with updated IPC codes
 NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAPLUS with the
 IPC reform
 NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
 USPAT2
 NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUIDB, and IFICDB
 NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
 INPADOC
 NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
 NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV
 NEWS 13 JAN 30 Saved answer limit increased
 NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency
 added to TULSA

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
 CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
 AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
 V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
 specific topic.

All use of STN is subject to the provisions of the STN Customer
 agreement. Please note that this agreement limits use to scientific
 research. Use for software development or design or implementation
 of commercial gateways or other similar uses is prohibited and may
 result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:22:26 ON 06 FEB 2006

=> file medline biosis caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 18:22:39 ON 06 FEB 2006

FILE 'BIOSIS' ENTERED AT 18:22:39 ON 06 FEB 2006
 Copyright (c) 2006 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 18:22:39 ON 06 FEB 2006
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s inorganic(s)phosphat?(s)remov?
 L1 192 INORGANIC(S) PHOSPHAT?(S) REMOV?

=> s l1(s)pyrophosphat?
 L2 8 L1(S) PYROPHOSPHAT?

=> d ti 12 1-8

L2 ANSWER 1 OF 8 MEDLINE on STN

TI Fluoride alters casein kinase II and alkaline phosphatase activity in vitro with potential implications for dentine mineralization.

L2 ANSWER 2 OF 8 MEDLINE on STN

TI Tissue differentiation and correlated changes in enzymatic activities during primary antler development in fallow deer (Dama dama).

L2 ANSWER 3 OF 8 MEDLINE on STN

TI Tightly bound pyrophosphate in Escherichia coli inorganic pyrophosphatase.

L2 ANSWER 4 OF 8 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Method of preparing polypeptides in a cell-free translation system.

L2 ANSWER 5 OF 8 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Fluoride alters casein kinase II and alkaline phosphatase activity in vitro with potential implications for dentine mineralization.

L2 ANSWER 6 OF 8 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI Tissue differentiation and correlated changes in enzymatic activities during primary antler development in fallow deer (Dama dama).

L2 ANSWER 7 OF 8 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI BEHAVIOR OF CHROMIUM IN SOILS PART 1 TRIVALENT FORMS.

L2 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

TI Methods for the Quantitative Estimation of Inorganic Phosphorus in Vegetable and Animal Substances

=> s inorganic(s)phosphat?(s)precipit?

L3 160 INORGANIC(S) PHOSPHAT?(S) PRECIPIT?

=> s l3(s)pyrophosphat?

L4 1 L3(S) PYROPHOSPHAT?

=> d ti 14

L4 ANSWER 1 OF 1 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI EFFECTS OF THE ADDITION OF CALCIUM ON THE COLLOIDAL STABILITY OF SOYMILK.

=> s inorganic(s)phosphat?(s)phosphofructosekinas?

L5 0 INORGANIC(S) PHOSPHAT?(S) PHOSPHOFRUCTOSEKINAS?

=> s inorganic(s)phosphat?(s)phosphofructokinas?

L6 57 INORGANIC(S) PHOSPHAT?(S) PHOSPHOFRUCTOKINAS?

=> d ti 16 1-57

L6 ANSWER 1 OF 57 MEDLINE on STN

TI Glycolysis in Entamoeba histolytica. Biochemical characterization of recombinant glycolytic enzymes and flux control analysis.

L6 ANSWER 2 OF 57 MEDLINE on STN

TI Mechanisms for increased glycolysis in the hypertrophied rat heart.

L6 ANSWER 3 OF 57 MEDLINE on STN

TI Proton transport in maize tonoplasts supported by fructose-1,6-bisphosphate cleavage. Pyrophosphate-dependent phosphofructokinase as a pyrophosphate-regenerating system.

L6 ANSWER 4 OF 57 MEDLINE on STN

TI Skeletal muscle phosphocreatine depletion depresses myocellular energy status during sepsis.

L6 ANSWER 5 OF 57 MEDLINE on STN
 TI Purification and characterization of pyrophosphate-dependent phosphofructokinase from phosphate-starved *Brassica nigra* suspension cells.

L6 ANSWER 6 OF 57 MEDLINE on STN
 TI Control of adenine nucleotide metabolism and glycolysis in vertebrate skeletal muscle during exercise.

L6 ANSWER 7 OF 57 MEDLINE on STN
 TI pH in human tumor xenografts and transplanted rat tumors: effect of insulin, inorganic phosphate, and m-iodobenzylguanidine.

L6 ANSWER 8 OF 57 MEDLINE on STN
 TI Relationships between the neuronal sodium/potassium pump and energy metabolism. Effects of K⁺, Na⁺, and adenosine triphosphate in isolated brain synaptosomes.

L6 ANSWER 9 OF 57 MEDLINE on STN
 TI **Inorganic** pyrophosphate: fructose-6-phosphate 1-phosphotransferase of the potato tuber is related to the major ATP-dependent **phosphofructokinase** of *E. coli*.

L6 ANSWER 10 OF 57 MEDLINE on STN
 TI Isotope exchange as a probe of the kinetic mechanism of pyrophosphate-dependent phosphofructokinase.

L6 ANSWER 11 OF 57 MEDLINE on STN
 TI Phosphorus NMR spectroscopy study of muscular enzyme deficiencies involving glycogenolysis and glycolysis.

L6 ANSWER 12 OF 57 MEDLINE on STN
 TI Phosphofructokinase from the epithelial cells of rat small intestine. Comparison of regulatory properties with those of skeletal muscle, liver and brain phosphofructokinase.

L6 ANSWER 13 OF 57 MEDLINE on STN
 TI **Inorganic phosphate** amplifies the effects of AMP and fructose-2,6-bisphosphate on yeast **phosphofructokinase**.

L6 ANSWER 14 OF 57 MEDLINE on STN
 TI Phosphate dependency of phosphofructokinase 2.

L6 ANSWER 15 OF 57 MEDLINE on STN
 TI Influence of **inorganic phosphate** on the kinetic properties of yeast **phosphofructokinase**.

L6 ANSWER 16 OF 57 MEDLINE on STN
 TI Mechanism of red cell 2,3-diphosphoglycerate increase in neonatal lambs.

L6 ANSWER 17 OF 57 MEDLINE on STN
 TI Effects of whole body UV-irradiation on oxygen delivery from the erythrocyte.

L6 ANSWER 18 OF 57 MEDLINE on STN
 TI Properties of phospho and dephospho forms of muscle phosphofructokinase.

L6 ANSWER 19 OF 57 MEDLINE on STN
 TI Regulation of glycolysis/fructolysis in buffalo spermatozoa.

L6 ANSWER 20 OF 57 MEDLINE on STN
 TI pH-dependent temperature sensitivity of rat lens phosphofructokinase.

L6 ANSWER 21 OF 57 MEDLINE on STN
 TI The effects of ammonium, **inorganic phosphate** and potassium ions on the activity of **phosphofructokinases** from muscle and nervous tissues of vertebrates and invertebrates.

L6 ANSWER 22 OF 57 MEDLINE on STN
 TI Myocardial adenine nucleotides, hexose **phosphates** and **inorganic phosphate**, and the regulation of **phosphofructokinase** activity during fluoroacetate poisoning in the rat.

L6 ANSWER 23 OF 57 MEDLINE on STN
 TI Kinetic properties of the **phosphofructokinase** from erythrocytes of rats and rabbits. I. The influence of potassium and ammonium ions and of **inorganic phosphate**.

L6 ANSWER 24 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Glycolysis in *Entamoeba histolytica* - Biochemical characterization of recombinant glycolytic enzymes and flux control analysis.

L6 ANSWER 25 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Mechanisms for increased glycolysis in the hypertrophied rat heart.

L6 ANSWER 26 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Proton transport in maize tonoplasts supported by fructose-1,6-bisphosphate cleavage. Pyrophosphate-dependent phosphofructokinase as a pyrophosphate-regenerating system.

L6 ANSWER 27 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Disruption of the phosphate-starvation response of *Brassica napus* by the fungicide phosphonate.

L6 ANSWER 28 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Purification and characterization of pyrophosphate-dependent phosphofructokinase from phosphate-starved *Brassica nigra* suspension cells.

L6 ANSWER 29 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI Control of adenine nucleotide metabolism and glycolysis in vertebrate skeletal muscle during exercise.

L6 ANSWER 30 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI The fungicide phosphonate disrupts the phosphate-starvation response in *Brassica nigra* seedlings.

L6 ANSWER 31 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI PH in human tumor xenografts and transplanted rat tumors: Effect of insulin, inorganic phosphate, and m-iodobenzylguanidine.

L6 ANSWER 32 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
 TI THE ENERGETIC STATE OF THE THERMOGENIC APPENDIX OF THE VOODOO LILY INFLORESCENCE A PHOSPHORUS-31 NMR STUDY.

L6 ANSWER 33 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI RELATIONSHIPS BETWEEN THE NEURONAL SODIUM POTASSIUM PUMP AND ENERGY METABOLISM EFFECTS OF POTASSIUM ION SODIUM ION AND ATP IN ISOLATED BRAIN SYNAPTOSOMES.

L6 ANSWER 34 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI **INORGANIC PYROPHOSPHATE FRUCTOSE-6-PHOSPHATE**
1-PHOSPHOTRANSFERASE OF THE POTATO TUBER IS RELATED TO THE MAJOR ATP-DEPENDENT **PHOSPHOFRUCTOKINASE** OF ESCHERICHIA-COLI.

L6 ANSWER 35 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI ISOTOPE EXCHANGE AS A PROBE OF THE KINETIC MECHANISM OF PYROPHOSPHATE-DEPENDENT PHOSPHOFRUCTOKINASE.

L6 ANSWER 36 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI BIOCHEMISTRY OF ENTAMOEBA A REVIEW.

L6 ANSWER 37 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI PHOSPHORUS NMR SPECTROSCOPY STUDY OF MUSCULAR ENZYME DEFICIENCIES INVOLVING GLYCOGENOLYSIS AND GLYCOLYSIS.

L6 ANSWER 38 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI THE ROLE OF INORGANIC PHOSPHATE IN THE REGULATION OF PFK ACTIVITY IN TOMATOES.

L6 ANSWER 39 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI PHOSPHOFRUCTOKINASE FROM THE EPITHELIAL CELLS OF RAT SMALL INTESTINE COMPARISON OF REGULATORY PROPERTIES WITH THOSE OF SKELETAL MUSCLE LIVER AND BRAIN PHOSPHOFRUCTOKINASE.

L6 ANSWER 40 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI IN-VIVO PHOSPHORUS-31 TOPOGRAPHIC MAGNETIC RESONANCE OF RIPENING AVOCADO FRUIT.

L6 ANSWER 41 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI **INORGANIC PHOSPHATE** AMPLIFIES THE EFFECTS OF AMP AND FRUCTOSE 2 6-BISPHOSPHATE ON YEAST SACCHAROMYCES-CEREVISIAE **PHOSPHOFRUCTOKINASE**.

L6 ANSWER 42 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI PHOSPHATE DEPENDENCY OF PHOSPHOFRUCTOKINASE 2 EC-2.7.1.-.

L6 ANSWER 43 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI SEQUENTIAL CHANGES IN RED CELL GLYCOLYTIC ENZYMES AND INTERMEDIATES AND POSSIBLE CONTROL MECHANISMS IN THE FIRST 2 MONTHS OF POSTNATAL LIFE IN LAMBS.

L6 ANSWER 44 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI INFLUENCE OF **INORGANIC PHOSPHATE** ON THE KINETIC PROPERTIES OF YEAST SACCHAROMYCES-CEREVISIAE **PHOSPHOFRUCTOKINASE** EC-2.7.1.11.

L6 ANSWER 45 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN

TI PLANT ENZYMES PHOSPHORYLATING FRUCTOSE-6-PHOSPHATE.

L6 ANSWER 46 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN

TI ACTIVATION OF THE PLASTID ISOZYME OF PHOSPHO FRUCTO KINASE EC-2.7.1.11
FROM DEVELOPING ENDOSPERM OF RICINUS-COMMUNIS BY FRUCTOSE 2 6 BIS
PHOSPHATE.

L6 ANSWER 47 OF 57 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on
STN

TI CHLOROPLAST PHOSPHO FRUCTO KINASE EC-2.7.1.11 IN THE GREEN ALGA
DUNALIELLA-MARINA PARTIAL PURIFICATION AND KINETIC AND REGULATORY
PROPERTIES.

L6 ANSWER 48 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI In Silico Exploration of the Fructose-6-Phosphate Phosphorylation Step in
Glycolysis: Genomic Evidence of the Coexistence of an Atypical
ATP-Dependent Along with a PPi-Dependent Phosphofructokinase in
Propionibacterium freudenreichii subsp. shermanii

L6 ANSWER 49 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI Effect of **inorganic phosphate** nutrition on the
molecular and kinetic properties of pyrophosphate-dependent
phosphofructokinase in Brassica nigra

L6 ANSWER 50 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI **Inorganic** pyrophosphate:fructose-6-**phosphate**
1-phosphotransferase of the potato tuber is related to the major
ATP-dependent **phosphofructokinase** of E. coli

L6 ANSWER 51 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI **Inorganic phosphate** amplifies the effects of AMP and
fructose-2,6-bisphosphate on yeast **phosphofructokinase**

L6 ANSWER 52 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI Influence of **inorganic phosphate** on the kinetic
properties of yeast **phosphofructokinase**

L6 ANSWER 53 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI Properties of carboxytransphosphorylase; pyruvate, **phosphate**
dikinase; pyrophosphate-**phosphofructokinase** and
pyrophosphate-acetate kinase and their roles in the metabolism of
inorganic pyrophosphate

L6 ANSWER 54 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI Effects of ammonium, **inorganic phosphate**, and
potassium ions on the activity of **phosphofructokinases** from
muscle and nervous tissues of vertebrates and invertebrates

L6 ANSWER 55 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI Myocardial adenine nucleotides, hexose **phosphates**, and
inorganic phosphate, and the regulation of
phosphofructokinase activity during fluoroacetate poisoning in the
rat

L6 ANSWER 56 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI Kinetic properties of the **phosphofructokinase** from erythrocytes
of rats and rabbits. 1. Influence of potassium and ammonium ions and of
inorganic phosphate

L6 ANSWER 57 OF 57 CAPLUS COPYRIGHT 2006 ACS on STN

TI Regulation of glycolysis in muscle

=>

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal652dmr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6 DEC 14 CA/CAPLUS to be enhanced with updated IPC codes
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAPLUS with the
IPC reform
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
USPAT2
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
INPADOC
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV
NEWS 13 JAN 30 Saved answer limit increased
NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency
added to TULSA

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:33:15 ON 08 FEB 2006

=> index bioscience medicine

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,

AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 10:33:28 ON 08 FEB 2006

73 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view search error messages that display as 0* with SET DETAIL OFF.

=> s inorgan?(s)phosphat?(s)pyrophosphat?

74 FILE AGRICOLA
17 FILE ANABSTR
1 FILE ANTE
6 FILE AQUALINE
18 FILE AQUASCI
27 FILE BIOENG
296 FILE BIOSIS
68 FILE BIOTECHABS
68 FILE BIOTECHDS
155 FILE BIOTECHNO
193 FILE CABA
179 FILE CAPLUS
5 FILE CEABA-VTB
4 FILE CONFSCI

18 FILES SEARCHED...

4 FILE CROPU
25 FILE DDFB
6 FILE DDFU
133 FILE DGENE
38 FILE DISSABS
25 FILE DRUGB
13 FILE DRUGU
3 FILE EMBAL
194 FILE EMBASE
172 FILE ESBIODASE
12* FILE FEDRIP
2 FILE FOMAD

33 FILES SEARCHED...

4 FILE FROSTI
41 FILE FSTA
337 FILE GENBANK
1 FILE HEALSAFE
194 FILE IFIPAT
20 FILE JICST-EPLUS
1 FILE KOSMET
176 FILE LIFESCI
311 FILE MEDLINE
9 FILE NIOSHTIC
8 FILE NTIS
4 FILE OCEAN
135 FILE PASCAL
14 FILE PROMT
13 FILE RDISCLOSURE

59 FILES SEARCHED...

214 FILE SCISEARCH
37 FILE TOXCENTER
4584 FILE USPATFULL
407 FILE USPAT2
9 FILE WATER
474 FILE WPIDS
1 FILE WPIFV
474 FILE WPINDEX
2 FILE IPA
1 FILE NAPRALERT
6 FILE NLDB

52 FILES HAVE ONE OR MORE ANSWERS, 73 FILES SEARCHED IN STNINDEX

L1 QUE INORGAN?(S) PHOSPHAT?(S) PYROPHOSPHAT?

=> d rank

F1	4584	USPATFULL
F2	474	WPIDS
F3	474	WPINDEX
F4	407	USPAT2
F5	337	GENBANK
F6	311	MEDLINE
F7	296	BIOSIS
F8	214	SCISEARCH
F9	194	EMBASE
F10	194	IFIPAT
F11	193	CABA
F12	179	CAPLUS
F13	176	LIFESCI
F14	172	ESBIOBASE
F15	155	BIOTECHNO
F16	135	PASCAL
F17	133	DGENE
F18	74	AGRICOLA
F19	68	BIOTECHABS
F20	68	BIOTECHDS
F21	41	FSTA
F22	38	DISSABS
F23	37	TOXCENTER
F24	27	BIOENG
F25	25	DDFB
F26	25	DRUGB
F27	20	JICST-EPLUS
F28	18	AQUASCI
F29	17	ANABSTR
F30	14	PROMT
F31	13	DRUGU
F32	13	RDISCLOSURE
F33	12*	FEDRIP
F34	9	NIOSHTIC
F35	9	WATER
F36	8	NTIS
F37	6	AQUALINE
F38	6	DDFU
F39	6	NLDB
F40	5	CEABA-VTB
F41	4	CONFSCI
F42	4	CROPU
F43	4	FROSTI
F44	4	OCEAN
F45	3	EMBAL
F46	2	FOMAD
F47	2	IPA
F48	1	ANTE
F49	1	HEALSAFE
F50	1	KOSMET
F51	1	WPIFV
F52	1	NAPRALERT

=> file f1-f4,f6-f11

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE
ENTRY
2.44

TOTAL
SESSION
2.65

FILE 'USPATFULL' ENTERED AT 10:35:48 ON 08 FEB 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 10:35:48 ON 08 FEB 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'USPAT2' ENTERED AT 10:35:48 ON 08 FEB 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 10:35:48 ON 08 FEB 2006

FILE 'BIOSIS' ENTERED AT 10:35:48 ON 08 FEB 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 10:35:48 ON 08 FEB 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 10:35:48 ON 08 FEB 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'IFIPAT' ENTERED AT 10:35:48 ON 08 FEB 2006
COPYRIGHT (C) 2006 IFI CLAIMS(R) Patent Services (IFI)

FILE 'CABA' ENTERED AT 10:35:48 ON 08 FEB 2006
COPYRIGHT (C) 2006 CAB INTERNATIONAL (CABI)

```
=> s inorgan?(s)phosphat?(s)pyrophosphat?
L2      6867 INORGAN?(S) PHOSPHAT?(S) PYROPHOSPHAT?

=> s l2 (s)(conver? or remov? or complex? or precipit?)
      2 FILES SEARCHED...
L3      819 L2 (S) (CONVER? OR REMOV? OR COMPLEX? OR PRECIPIT?)

=> s l3(s)enzym?
L4      183 L3(S) ENZYM?

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5      164 DUP REM L4 (19 DUPLICATES REMOVED)

=> s l3(s)phosphofructokinas?
L6      24 L3(S) PHOSPHOFRUCTOKINAS?

=> dup rem l6
PROCESSING COMPLETED FOR L6
L7      23 DUP REM L6 (1 DUPLICATE REMOVED)

=> d ti l5 1-164
```

L5 ANSWER 1 OF 164 USPATFULL on STN
TI Identification of novel e2f target genes and use thereof

L5 ANSWER 2 OF 164 USPATFULL on STN
TI Cleaning composition

L5 ANSWER 3 OF 164 USPATFULL on STN
TI Gene expression profiling of colon cancer with DNA arrays

L5 ANSWER 4 OF 164 USPATFULL on STN
TI Carbohydrate purification using ultrafiltration, reverse osmosis and nanofiltration

L5 ANSWER 5 OF 164 USPATFULL on STN

=> d ti l7 1-23

L7 ANSWER 1 OF 23 USPATFULL on STN
TI Methods and apparatus for gel-free qualitative and quantitative proteome analysis, and uses therefore

L7 ANSWER 2 OF 23 USPATFULL on STN
TI Acyl-nucleotide probes and methods of their synthesis and use in proteomic analysis

L7 ANSWER 3 OF 23 USPATFULL on STN DUPLICATE 1
TI Methods and apparatuses for gel-free qualitative and quantitative proteome analysis, and uses therefore

L7 ANSWER 4 OF 23 USPATFULL on STN
TI Matrices for drug delivery and methods for making and using the same

L7 ANSWER 5 OF 23 USPATFULL on STN
TI Translational profiling

L7 ANSWER 6 OF 23 USPATFULL on STN
TI Fusion proteins comprising DP-178 and other viral fusion inhibitor peptides useful for treating aids

L7 ANSWER 7 OF 23 USPATFULL on STN
TI Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids

L7 ANSWER 8 OF 23 USPATFULL on STN
TI Compositions and methods for modeling bacillus subtilis metabolism

L7 ANSWER 9 OF 23 USPATFULL on STN
TI Yeast proteome analysis

L7 ANSWER 10 OF 23 USPATFULL on STN
TI Libraries of expressible gene sequences

L7 ANSWER 11 OF 23 USPATFULL on STN
TI Matrices for drug delivery and methods for making and using the same

L7 ANSWER 12 OF 23 USPATFULL on STN
TI Libraries of expressible gene sequences

L7 ANSWER 13 OF 23 USPATFULL on STN
TI Models and methods for determining systemic properties of regulated reaction networks

L7 ANSWER 14 OF 23 USPATFULL on STN
TI Nucleotide sequence of the mycoplasma genitalium genome, fragments thereof, and uses thereof

L7 ANSWER 15 OF 23, USPATFULL on STN
TI Regulation and manipulation of sucrose content in sugarcane

L7 ANSWER 16 OF 23 USPATFULL on STN
TI Methods for identifying drug targets based on genomic sequence data

L7 ANSWER 17 OF 23 USPATFULL on STN
TI Polynucleotides and polypeptides derived from corn ear

L7 ANSWER 18 OF 23 USPATFULL on STN
TI Matrices for drug delivery and methods for making and using the same

L7 ANSWER 19 OF 23 USPAT2 on STN

TI Genome DNA of bacterial symbiont of aphids

L7 ANSWER 20 OF 23 USPATFULL on STN

TI Genomic DNA sequences of ashbya gossypii and uses thereof

L7 ANSWER 21 OF 23 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN

TI In vitro enzymatic synthesis of deoxyribonucleosides comprises reacting deoxyribose 1-phosphate and a nucleobase to form a deoxyribonucleoside and an inorganic phosphate.

L7 ANSWER 22 OF 23 CABA COPYRIGHT 2006 CABI on STN

TI Alternate routes for starch synthesis in developing grains of wheat and sorghum: indirect evidence through its regulation by inorganic phosphates and organic acids.

L7 ANSWER 23 OF 23 CABA COPYRIGHT 2006 CABI on STN

TI Transgenic potato plants with strongly decreased expression of pyrophosphate:fructose-6-phosphate phosphotransferase show no visible phenotype and only minor changes in metabolic fluxes in their tubers.

=> d ibib abs 4 8 12 17 24 30-31 56-57 62 65 66 71-72 96 111 125 128 129 135 15

L5 ANSWER 4 OF 164 USPATFULL on STN

ACCESSION NUMBER: 2005:309655 USPATFULL

TITLE: Carbohydrate purification using ultrafiltration, reverse osmosis and nanofiltration

INVENTOR(S): DeFrees, Shawn, North Wales, PA, UNITED STATES

PATENT ASSIGNEE(S): Neose Technologies, Horsham, PA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005269265	A1	20051208
APPLICATION INFO.:	US 2005-198839	A1	20050804 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-104609, filed on 22 Mar 2002, GRANTED, Pat. No. US 6936173 Continuation of Ser. No. US 1997-947775, filed on 9 Oct 1997, GRANTED, Pat. No. US 6454946		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-28226P	19961010 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORGAN, LEWIS & BOCKIUS LLP (SF), 2 PALO ALTO SQUARE, PALO ALTO, CA, 94306, US	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1-30	
LINE COUNT:	1545	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods for purifying carbohydrates, including oligosaccharides, nucleotide sugars, and related compounds, by use of ultrafiltration, nanofiltration and/or reverse osmosis. The carbohydrates are purified away from undesired contaminants such as compounds present in reaction mixtures following enzymatic synthesis or degradation of oligosaccharides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 164 USPATFULL on STN

ACCESSION NUMBER: 2005:254953 USPATFULL

TITLE: Mannosyl transfer with regeneration of GDP-mannose

INVENTOR(S): Wong, Chi-Huey, Rancho Santa Fe, CA, UNITED STATES

PATENT ASSIGNEE(S): The Scripps Research Institute (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005221447	A1	20051006
APPLICATION INFO.:	US 2005-145810	A1	20050606 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2002-262503, filed on 1 Oct 2002, GRANTED, Pat. No. US 6919440 Division of Ser. No. US 1993-122229, filed on 15 Sep 1993, GRANTED, Pat. No. US 6485930		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WELSH & KATZ, LTD, 120 S RIVERSIDE PLAZA, 22ND FLOOR, CHICAGO, IL, 60606, US		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1-12		
LINE COUNT:	1068		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A one-pot glycosylation reaction is disclosed in which a mannosyl (Man) group is enzymatically transferred to an acceptor molecule. The starting glycoside is a mannosyl 1-phosphate that is enzymatically converted to its GDP derivative via UTP and a pyrophorylase. The formed GDP derivative is used in the enzyme-catalyzed glycosyl transfer. That enzyme-catalyzed glycosyl transfer to an acceptor releases GDP that is enzymatically converted to GTP for further conversion of mannosyl 1-phosphate into its GDP derivative. Also disclosed are a recombinant α 1,2-mannosyltransferase that is enzymatically active, is dispersible in an aqueous reaction medium, and free of the transmembrane portion of the native enzyme, as well as DNA encoding that transferase, an expression vector containing exogenous DNA that encodes that enzyme and E. coli cells containing that vector.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 164 USPATFULL on STN

ACCESSION NUMBER: 2005:220892 USPATFULL

TITLE: Enzymes

INVENTOR(S): Yang, Junming, San Jose, CA, UNITED STATES
Dyung Lu, Aina M., San Jose, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Elliott, Vicki S., San Jose, CA, UNITED STATES
Warren, Bridget A., Encinitas, CA, UNITED STATES
Duggan, Brendan M., Sunnyvale, CA, UNITED STATES
Forsythe, Ian J., Redwood City, CA, UNITED STATES
Lee, Ernestine A., Castro Valley, CA, UNITED STATES
Hafalia, April J.A., Santa Clara, CA, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Chawla, Narinder K., Union City, CA, UNITED STATES
Baughn, Mariah R., San Leandro, CA, UNITED STATES
Becha, Shanya D., Castro Valley, CA, UNITED STATES
Gorvad, Ann E., Livermore, CA, UNITED STATES
Tran, Uyen K., San Jose, CA, UNITED STATES
Li, Joana X., San Francisco, CA, UNITED STATES
Yao, Monique G., Carmel, IN, UNITED STATES
Ison, Craig H., San Jose, CA, UNITED STATES
Griffin, Jennifer A., Fremont, CA, UNITED STATES
Lee, Soo Yeun, Daly City, CA, UNITED STATES
Chang, Hsin-Ru, Belmont, CA, UNITED STATES
Emerling, Brooke M., Palo Alto, CA, UNITED STATES
Tang, Tom Y., San Jose, CA, UNITED STATES
Lal, Preeti G., Santa Clara, CA, UNITED STATES
Kable, Amy E., San Francisco, CA, UNITED STATES
Marquis, Joseph P., San Jose, CA, UNITED STATES
Jiang, Xin, Saratoga, CA, UNITED STATES
Jackson, Alan A., Los Gatos, CA, UNITED STATES
Zebarjadian, Yeganeh, San Francisco, CA, UNITED STATES

Swarnakar, Anita, San Francisco, CA, UNITED STATES
 Wilson, Amy D., Belmont, CA, UNITED STATES
 Jin, Pei, Palo Alto, CA, UNITED STATES
 Richardson, Thomas W., Redwood City, CA, UNITED STATES
 Bhatia, Umesh, San Jose, CA, UNITED STATES
 Burrill, John D., Redwood City, CA, UNITED STATES
 Lee, Sally, San Francisco, CA, UNITED STATES
 Blake, Julie J., San Francisco, CA, UNITED STATES
 Ho, Anne, Sunnyvale, CA, UNITED STATES
 Zheng, Wenjin, Mountain View, CA, UNITED STATES
 Gao, Jin, Sunnyvale, CA, UNITED STATES
 Incyte Corporation, Palo Alto, CA, UNITED STATES, 94304
 (U.S. corporation)

PATENT ASSIGNEE(S):

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005191627	A1	20050901
APPLICATION INFO.:	US 2003-491183	A1	20020926 (10)
	WO 2002-US31096		20020926
			20040329 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-326388P	20010928 (60)
	US 2003-328979P	20011012 (60)
	US 2003-346034P	20011019 (60)
	US 2003-348284P	20011026 (60)
	US 2003-338048P	20011108 (60)
	US 2003-332340P	20011116 (60)
	US 2003-368799P	20020329 (60)
	US 2003-368722P	20020329 (60)
	US 2003-381588P	20020517 (60)
	US 2003-387119P	20020607 (60)
	US 2003-390662P	20020621 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: INCYTE CORPORATION, EXPERIMENTAL STATION, ROUTE 141 &
 HENRY CLAY ROAD, BLDG. E336, WILMINGTON, DE, 19880, US
 NUMBER OF CLAIMS: 30
 EXEMPLARY CLAIM: 1
 LINE COUNT: 19139

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Various embodiments of the invention provide human enzymes (ENZM) and polynucleotides which identify and encode ENZM. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of ENZM.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 17 OF 164 USPATFULL on STN
 ACCESSION NUMBER: 2005:158186 USPATFULL
 TITLE: Cell-based assay for identifying peptidase inhibitors
 INVENTOR(S): Fang, Hong, Chapmansboro, TN, UNITED STATES
 Green, Neil, Chapmansboro, TN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005136394	A1	20050623
APPLICATION INFO.:	US 2004-842846	A1	20040511 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-480625P	20030623 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FULBRIGHT & JAWORSKI L.L.P., SUITE 2400, 600 CONGRESS
AVENUE, AUSTIN, TX, 78701-3271, US
NUMBER OF CLAIMS: 25
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 2115

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides assays for the identification of inhibitors of endopeptidase toxins. The assays utilize genetically engineered yeast cells that contain a conditionally expressed endopeptidase toxin. When conditions for expression of the toxin are met, the toxin cleaves a yeast (natural or engineered) peptide product that is required for yeast survival. If the yeast is grown in the presence of an candidate substance that is an inhibitor of the toxin, the yeast survives, thereby providing a rapid and sensitive identification of the inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 24 OF 164 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
ACCESSION NUMBER: 2005-296144 [30] WPIDS
DOC. NO. CPI: C2005-091609
TITLE: Inhibiting misincorporation of a terminator in a single base primer extension reaction, useful in analyzing nucleic acid variations, by enzymatically removing inorganic pyrophosphate prior to or during a single base extension reaction.
DERWENT CLASS: B04 D16
INVENTOR(S): BUZBY, P
PATENT ASSIGNEE(S): (PEKE) PERKINELMER LAS INC
COUNTRY COUNT: 108
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG																	
WO 2005033328	A2	20050414	(200530)*	EN	59																	
RW:	AT	BE	BG	BW	CH	CY	CZ	DE	DK	EA	EE	ES	FI	FR	GB	GH	GM	GR	HU	IE	IT	KE
	LS	LU	MC	MW	MZ	NA	NL	OA	PL	PT	RO	SD	SE	SI	SK	SL	SZ	TR	TZ	UG	ZM	ZW
W:	AE	AG	AL	AM	AT	AU	AZ	BA	BB	BG	BR	BW	BY	BZ	CA	CH	CN	CO	CR	CU	CZ	DE
	DK	DM	DZ	EC	EE	EG	ES	FI	GB	GD	GE	GH	GM	HR	HU	ID	IL	IN	IS	JP	KE	KG
	KP	KR	KZ	LC	LK	LR	LS	LT	LU	LV	MA	MD	MG	MK	MN	MW	MX	MZ	NA	NI	NO	NZ
	OM	PG	PH	PL	PT	RO	RU	SC	SD	SE	SG	SK	SL	SY	TJ	TM	TN	TR	TT	TZ	UA	UG
	US	UZ	VC	VN	YU	ZA	ZM	ZW														

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2005033328	A2	WO 2004-US32164	20040930

PRIORITY APPLN. INFO: US 2003-481443P 20030930
AN 2005-296144 [30] WPIDS
AB WO2005033328 A UPAB: 20050512

NOVELTY - Inhibiting misincorporation of a terminator in a single base primer extension reaction comprises providing a product of a nucleic acid synthesis reaction, the product comprising a nucleic acid template and a quantity of inorganic pyrophosphate, and incubating the product and an inorganic pyrophosphatase to decrease the quantity of pyrophosphate.

DETAILED DESCRIPTION - The method of inhibiting misincorporation of a terminator in a single base primer extension reaction cited above further comprises providing a product of a nucleic acid synthesis reaction, the product comprising a nucleic acid template and a quantity of inorganic

pyrophosphate, incubating the product and an inorganic pyrophosphatase to decrease the quantity of pyrophosphate, to yield a purified reaction product, combining the purified reaction product, a primer, a terminator having a detectable label, and a polymerase to form a mixture, and incubating the mixture to extend the primer by addition of the terminator in a single base primer extension reaction, where decreasing the quantity of inorganic pyrophosphate in the product of a nucleic acid synthesis reaction inhibits pyrophosphorolysis in the single base primer extension reaction, so as to inhibit misincorporation of a terminator.

INDEPENDENT CLAIMS are also included for the following:

(1) a composition, comprising an inorganic pyrophosphatase, a residual component removal agent selected from an alkaline phosphatase, an exonuclease, and their combination, and a carrier;

(2) a composition for use in reducing misincorporation of a terminator in a single base extension reaction, comprising an acyclo nucleoside terminator, an inorganic pyrophosphate as mentioned, a pyrophosphatase and a carrier;

(3) a commercial package comprising a mixture of an exonuclease, an alkaline phosphatase, an inorganic pyrophosphatase as mentioned, and a carrier, and instructions for use of the mixture in a primer extension reaction; and

(4) a process for determining the identity of a nucleotide at an interrogation site.

USE - The inorganic pyrophosphatase is useful in a process for identification of an interrogation site by single base extension (claimed). The methods and compositions of the present invention are also useful for detecting and characterizing a specified nucleotide in a nucleic acid sequence, in particular for reducing misincorporation of a labeled nucleotide or nucleotide analog in a primer extension reaction and for analyzing nucleic acid variations, such as single nucleotide polymorphisms.

Dwg.0/3

L5 ANSWER 30 OF 164 USPTAFULL on STN
 ACCESSION NUMBER: 2004:327408 USPTAFULL
 TITLE: Glycorandomization and production of novel vancomycin analogs
 INVENTOR(S): Thorson, Jon, Middleton, WI, UNITED STATES
 PATENT ASSIGNEE(S): Wisconsin Alumni Research Foundation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004259228	A1	20041223
APPLICATION INFO.:	US 2003-670073	A1	20030924 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-109672, filed on 1 Apr 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-279682P	20010330 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GODFREY & KAHN, S.C., 780 N. WATER STREET, MILWAUKEE, WI, 53202	
NUMBER OF CLAIMS:	43	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	17 Drawing Page(s)	
LINE COUNT:	3698	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides combinatorial methods for rapidly generating a diverse library of glycorandomized structures, comprising incubating one or more aglycons and a pool of NDP-sugars in the presence of a glycosyltransferase. The glycosyltransferase may be one that is associated with or involved in production of natural secondary metabolites, or one which is putatively associated with or involved in

production of natural secondary metabolites. The glycosyltransferase may show significant flexibility with respect to its NDP-sugar donors and/or its aglycons. NDP-sugar donors may be commercially available, or may be produced by utilizing mutant or wild type nucleotidyltransferases significant flexibility with respect to their substrates.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 31 OF 164 USPATFULL on STN
ACCESSION NUMBER: 2004:315541 USPATFULL
TITLE: Method of making teprenone
INVENTOR(S): Saucy, Gabriel G., Essex Fells, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004249219	A1	20041209
APPLICATION INFO.:	US 2001-899418	A1	20010703 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-215897P	20000705 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SHERIDAN ROSS PC, 1560 BROADWAY, SUITE 1200, DENVER, CO, 80202	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	1388	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention is directed to an efficient and economical method of making teprenone. Teprenone is synthesized by converting geranylgeraniol to teprenone by a novel route. The method of synthesis can begin with geranylgeraniol obtained from a biological source such as fermentation of a microorganism capable of producing geranylgeranyl or enzymatic synthesis in a cell free system to produce predominantly the 5E isomer of teprenone. The chemical synthesis proceeds with retention of configuration such that the teprenone produced has the isomeric configuration of the geranylgeraniol starting material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 56 OF 164 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
ACCESSION NUMBER: 2004-698721 [68] WPIDS
CROSS REFERENCE: 2004-698712 [68]
DOC. NO. CPI: C2004-247100
TITLE: Preparing plasmid, comprises preparing cleared host cell lysate, and enzymatically converting open circular plasmid obtained from lysate or from unintentional conversion of supercoiled plasmid from lysate, to supercoiled plasmid.
DERWENT CLASS: B04 D16
INVENTOR(S): HYMAN, E D
PATENT ASSIGNEE(S): (HYMA-I) HYMAN E D
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2004191871	A1	20040930	(200468)*		17

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
-----------	------	-------------	------

PRIORITY APPLN. INFO: US 2003-396880 20030325

AN 2004-698721 [68] WPIDS

CR 2004-698712 [68]

AB US2004191871 A UPAB: 20041026

NOVELTY - Preparing (M1) plasmid from host cells which contain the plasmid, comprises preparing a cleared lysate of the host cells, and in vitro enzymatically converting open circular plasmid to supercoiled plasmid.

DETAILED DESCRIPTION - Preparing (M1) plasmid from host cells which contain the plasmid, comprises preparing a cleared lysate of the host cells, and in vitro enzymatically converting open circular plasmid to supercoiled plasmid, where the open circular plasmid is obtained from the cleared lysate or obtained from supercoiled plasmid from the cleared lysate which is beforehand unintentionally converted to open circular plasmid.

INDEPENDENT CLAIMS are also included for the following:

(1) an enzyme composition (C1) useful for converting unligatable open circular plasmid to supercoiled plasmid comprising:

(i) DNA gyrase, DNA ligase, polynucleotide kinase, and 3'-phosphatase;

(ii) DNA polymerase I, DNA ligase, DNA gyrase, and not comprising a primase enzyme;

(iii) 3'-deblocking enzyme, DNA polymerase I, DNA ligase and DNA gyrase; or

(iv) DNA polymerase I, DNA ligase, DNA gyrase, and one or more exonucleases, where the exonucleases selectively degrade linear chromosomal DNA without degrading open circular plasmid, relaxed covalently closed circular plasmid, and supercoiled plasmid; and

(2) preparing highly supercoiled plasmid from host cells which contain host supercoiled plasmid, comprising preparing a cleared lysate of the host cells, where the cleared lysate comprises the host supercoiled plasmid, enzymatically in vitro converting open circular plasmid to supercoiled plasmid, where the open circular plasmid is obtained from the cleared lysate or obtained from supercoiled plasmid from the cleared lysate which is beforehand unintentionally converted to open circular plasmid, and incubating in vitro the host supercoiled plasmid with DNA gyrase in the presence of DNA gyrase nucleotide cofactor, where the host supercoiled plasmid is further supercoiled.

USE - (M1) is useful for preparing plasmid from host cells which contain the plasmid (claimed).

ADVANTAGE - (M1) provides increased supercoiled plasmid yield. The theoretical maximum yield of supercoiled plasmid is 100% of starting plasmid. (M1) avoids nicking damage in the initial plasmid processing, as any nicked plasmid will be converted to supercoiled plasmid. (M1) prepares large plasmids, which tend to have a higher percentage of open circular plasmid due to their larger size. The gyrase incubation increases the extent of supercoiling. The increased supercoiled state could create a more condensed plasmid molecule with potentially greater transformability. The DNA gyrase incubation converts all plasmid to a more highly supercoiled state.

DESCRIPTION OF DRAWING(S) - The figure shows a method of preparing plasmid from host cell which contains the plasmid.
Dwg.1/1

L5 ANSWER 57 OF 164 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN

ACCESSION NUMBER: 2004-280268 [26] WPIDS

DOC. NO. NON-CPI: N2004-221971

DOC. NO. CPI: C2004-108059

TITLE: Stabilization reagent composition for stabilizing blood sample containing platelets, has reactants that generate multiple species of formaldehyde-ammonium complexes, inhibitors of phosphatase and protease enzymatic

activities.
 DERWENT CLASS: A89 A96 B04 B05 D16 S03
 INVENTOR(S): MAPLES, J A; CHARIE, L A; FLAGLER, D J; MILLS, R A;
 TIMMONS, R
 PATENT ASSIGNEE(S): (MAPL-I) MAPLES J A; (BECI) BECKMAN COULTER INC; (COUS)
 COULTER INT CORP
 COUNTRY COUNT: 29
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 2004038424	A1	20040226	(200426)*		31
WO 2004017895	A2	20040304	(200426)	EN	
RW: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO					
SE SI SK TR					
W: JP					
US 6913932	B2	20050705	(200544)		
EP 1552269	A2	20050713	(200546)	EN	
R: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT					
RO SE SI SK TR					
JP 2005536550	W	20051202	(200582)		41

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
US 2004038424	A1	US 2002-226825	20020823
WO 2004017895	A2	WO 2003-US24426	20030806
US 6913932	B2	US 2002-226825	20020823
EP 1552269	A2	EP 2003-793016	20030806
		WO 2003-US24426	20030806
JP 2005536550	W	WO 2003-US24426	20030806
		JP 2004-530872	20030806

FILING DETAILS:

PATENT NO	KIND	PATENT NO
EP 1552269	A2 Based on	WO 2004017895
JP 2005536550	W Based on	WO 2004017895

PRIORITY APPLN. INFO: US 2002-226825 20020823
 AN 2004-280268 [26] WPIDS
 AB US2004038424 A UPAB: 20040421

NOVELTY - A stabilization reagent composition (I) comprising reactants that generate multiple species of formaldehyde-ammonium complexes, at least one inhibitor of phosphatase enzymatic activity, and at least one inhibitor of protease enzymatic activity, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) a stabilized blood sample (II) containing platelets treated with (I);
- (2) a kit comprising:
 - (a) as a first separate component, an aliphatic aldehyde of 1-4 carbon atoms in liquid or powder form or reactants that upon hydrolysis generate formaldehyde;
 - (b) as a second separate component, a solution comprising an ammonium salt solution, where the component has a physiological pH that does not adversely effect the stabilizing function of the composition;
 - (c) at least one inhibitor of phosphatase enzymatic activity;
 - (d) at least one inhibitor of protease enzymatic activity; and
 - (e) instructions for mixing the above components prior to contacting the mixture with a blood sample containing platelets immediately upon withdrawal from the body; and
- (3) assessing the efficacy of a blood cell stabilizing reagent

comprising measuring platelet activation by contacting a blood sample which has been treated with a cell-stabilizing reagent composition with an activating material that activates cellular response by causing physical and/or enzymatic changes in platelets, storing the sample at 20-25 deg. C for 72 hours, and determining the change in expression of CD62p on platelets in the sample compared with the expression of CD62p on platelets in a sample that has not been treated with the reagent composition, where the percentage of platelets expressing the CD62p antigen in the reagent treated samples is less than that percentage in an untreated sample stored for the same duration.

USE - (I) is useful for stabilizing blood cells in a blood sample containing platelets which involves contacting the sample with (I), where cells in the sample are characterized by a stabilized expression of CD62p on platelets in the sample for at least 24 hours after the treatment, where the treated sample maintains plus or minus 20% of the number of CD62p positive platelets that would be found in the blood sample, when the sample is measured without treatment immediately after withdrawal from the body. The method further comprises the step of drawing a blood sample into a calcium chelating anticoagulant or a coagulation pathway inhibitor prior to the contacting step. The method further comprises measuring platelet activation potential by contacting the sample with an activating material that is known to activate cellular response by causing physical and/or enzymatic changes in platelets and an associated increase in CD62p expression, storing the sample at 20-25 deg. C for 72 hours, and determining the change in expression of CD62p on platelets in the sample compared with the expression of CD62p on platelets in a sample untreated with the reagent composition, where the percentage of platelets expressing the CD62p antigen in the reagent treated samples is less than that percentage in an untreated sample stored for the same duration. The activating material is a solution of phorbol 12-myristate 13-acetate (PMA) that is added to a final concentration of 0.001-5 micro M in the sample. The change in percentage of CD62p platelets indicative of stabilization is measured by flow cytometry according to the formula: (Parameter C minus Parameter A) is greater than (Parameter D minus Parameter B), where, Parameter A is the percentage of CD62p positive platelets in an anticoagulated blood sample containing no stabilization reagent composition, Parameter B is the percentage of CD62p positive platelets in an anticoagulated blood sample incubated with the stabilization reagent composition for one hour, Parameter C is the percentage of CD62p positive platelets in an anticoagulated blood sample containing no stabilization reagent composition to which the PMA is added to a concentration 0.001-5 micro M and incubated for up to one hour, and Parameter D is the percentage of CD62p positive platelets in the anticoagulated blood sample containing the stabilization reagent to which the PMA is added to a concentration 0.001-5 micro M and incubated for up to one hour. The percentage of CD62p positive platelets in the blood containing stabilization reagent does not change more than 20% within the first hour after addition of the PMA (all claimed).

ADVANTAGE - The composition prevents or reduces cellular activation and response to environmental change without changing the antigenic makeup of the cells. The treated sample has the same state of platelet activation that is found in an untreated blood sample that is measured immediately upon withdrawal from the body. The presence of stabilizer prevents post-withdrawal activation of the platelets in the sample by in vitro environmental conditions. The presence of the stabilizer in the blood samples stabilizes the platelet activation state so that the percentage of CD62p platelets in the stabilized blood sample increases by no more than 20% over the percentage of CD62p platelets in the blood sample measured immediately upon withdrawal. The composition and methods stabilize in a donor's withdrawn blood sample for at least 24 hours the percentage of CD62p platelets. This stabilization of the blood sample thereby enables accurate diagnosis of disease based on percentage of CD62p platelets in blood samples that are stored prior to evaluation. Thus, in the case of a healthy donor, the methods and compositions permit evaluation of the blood sample by providing a state of platelet activation that is not unduly high

due to in vitro environmental conditions. In the case of an unhealthy donor, the methods and compositions permit evaluation of the blood sample by providing a state of platelet activation that is not unduly low due to in vitro environmental conditions.
Dwg.0/13

L5 ANSWER 62 OF 164 USPATFULL on STN DUPLICATE 5
ACCESSION NUMBER: 2003:213620 USPATFULL
TITLE: In situ screening to optimize variables in organic reactions
INVENTOR(S): Berkowitz, David B., Lincoln, NE, UNITED STATES
Bose, Mohua, La Jolla, CA, UNITED STATES
Choi, Sungjo, Chonan-City, KOREA, REPUBLIC OF
PATENT ASSIGNEE(S): University of Nebraska, Lincoln, NE, UNITED STATES
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003148257	A1	20030807
	US 6974665	B2	20051213
APPLICATION INFO.:	US 2002-235950	A1	20020906 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-386438P	20020607 (60)
	US 2002-371159P	20020410 (60)
	US 2001-317810P	20010906 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BANNER & WITCOFF, 1001 G STREET N W, SUITE 1100,
WASHINGTON, DC, 20001
NUMBER OF CLAIMS: 55
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 11 Drawing Page(s)
LINE COUNT: 3066

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A biphasic process for rapid screening of organic reactions comprising monitoring relative rates of parallel organic reactions. The screening process is suitable to determine the efficacy of different reactants, process conditions, and process enhancers such as catalysts or promoters. The biphasic process also allows multiple samples to be analyzed/monitored simultaneously. In addition because enzymes are used to monitor the reaction product in this invention, when that product is chiral and an enantio-discriminating enzyme is used to monitor the product, in addition to the relative rates, enantioselectivities of a set of parallel organic reactions can also be determined. The monitoring is done in situ and thus removal of aliquots for separate testing is unnecessary

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 65 OF 164 USPATFULL on STN DUPLICATE 8
ACCESSION NUMBER: 2003:71370 USPATFULL
TITLE: Amplification process
INVENTOR(S): Clark, Duncan Roy, Farnborough, UNITED KINGDOM
Vincent, Suzanne Patricia, Farnborough, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003049655	A1	20030313
	US 6951744	B2	20051004
APPLICATION INFO.:	US 2002-135807	A1	20020430 (10)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: GB 2001-10501 20010430
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JOHN S. PRATT, ESQ, KILPATRICK STOCKTON, LLP, 1100
PEACHTREE STREET, SUITE 2800, ATLANTA, GA, 30309
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 1571

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method for conducting a nucleic acid amplification reaction, said method comprising forming an amplification reaction mixture in the presence of sufficient of a pyrophosphate salt to prevent primer extension taking place, digesting said pyrophosphate salt with a pyrophosphatase enzyme (PPase), and subjecting said reaction mixture to conditions such that an amplification reaction may proceed.

This can be used as a "hot start" amplification.

Particular novel pyrophosphatase enzymes for use in the method are also described and claimed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 66 OF 164 USPATFULL on STN DUPLICATE 9
ACCESSION NUMBER: 2003:64673 USPATFULL
TITLE: 5'-thio phosphate directed ligation of oligonucleotides and use in detection of single nucleotide polymorphisms
INVENTOR(S): Bandaru, Rajanikanth, Corelville, IA, UNITED STATES
Kumar, Gyanendra, Guilford, CT, UNITED STATES
PATENT ASSIGNEE(S): Bandaru and Kumar (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003044794	A1	20030306
	US 6635425	B2	20031021
APPLICATION INFO.:	US 2001-910372	A1	20010720 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-259918P	20010105 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Alan J. Grant, Esq., c/o Carella, Byrne, Bain, Gilfillan,, Cecchi, Stewart & Olstein, 6 Becker Farm Road, Roseland, NJ, 07068	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	21 Drawing Page(s)	
LINE COUNT:	1835	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel method for ligation of oligonucleotides containing 5'-phosphorothioates on complementary templates by the action of DNA ligases. This reaction is readily applied to the synthesis of a single stranded circular DNA containing a phosphorothioate linkage at the site of ligation junction. The efficiency of 5'-phosphorothioate directed ligation reaction by ATP dependent DNA ligase reaction is similar to conventional 5'-phosphate ligation. The utility of enzymatic ligation in probing specific sequences of DNA is also described. The present invention also provides a novel non-enzymatic ligation of 5'-phosphorothioates that has been applied to the synthesis of single strand phosphorothioate and phosphate circular DNA. A process for detecting the presence of a mismatch in an otherwise complementary pair of oligonucleotides is disclosed using an enzyme-based technique which shows the presence of a mismatch by failing

to form a ligated single stranded DNA circle that can optionally be amplified using standard methods of rolling circle amplification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 71 OF 164 USPATFULL on STN
ACCESSION NUMBER: 2003:207209 USPATFULL
TITLE: Methods for enzymatic conversion of GDP-mannose to GDP-fucose
INVENTOR(S): Sjoberg, Eric R., San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): Cytel Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003143567	A1	20030731
APPLICATION INFO.:	US 2002-206655	A1	20020725 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-231905, filed on 14 Jan 1999, GRANTED, Pat. No. US 6500661		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-71076P	19980115 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834	
NUMBER OF CLAIMS:	55	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	2449	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods for practical enzymatic conversion of GDP-mannose to GDP-fucose. These methods are useful for efficient synthesis of reactants used in the synthesis of fucosylated oligosaccharides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 72 OF 164 USPATFULL on STN
ACCESSION NUMBER: 2003:194592 USPATFULL
TITLE: Nucleic acids useful for enzymatic conversion of GDP-mannose to GDP-fucose
INVENTOR(S): Sjoberg, Eric R., San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): Cytel Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003134403	A1	20030717
APPLICATION INFO.:	US 2002-206485	A1	20020725 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-231905, filed on 14 Jan 1999, GRANTED, Pat. No. US 6500661		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-71076P	19980115 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834	
NUMBER OF CLAIMS:	55	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	2445	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods for practical enzymatic conversion of

GDP-mannose to GDP-fucose. These methods are useful for efficient synthesis of reactants used in the synthesis of fucosylated oligosaccharides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 96 OF 164 USPATFULL on STN
ACCESSION NUMBER: 2002:287597 USPATFULL
TITLE: Practical in vitro sialylation of recombinant glycoproteins
INVENTOR(S): Paulson, James C., Del Mar, CA, UNITED STATES
Bayer, Robert J., San Diego, CA, UNITED STATES
Sjoberg, Eric, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): Neose Technologies, Inc., Horsham, PA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002160460	A1	20021031
APPLICATION INFO.:	US 2002-81456	A1	20020221 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-7741, filed on 15 Jan 1998, GRANTED, Pat. No. US 6399336		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-35710P	19970116 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834	
NUMBER OF CLAIMS:	58	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1142	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods for practical in vitro sialylation of glycoproteins, including recombinantly produced glycoproteins. The methods are useful for large-scale modification of sialylation patterns.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 111 OF 164 USPATFULL on STN
ACCESSION NUMBER: 2002:217057 USPATFULL
TITLE: Enzymatic synthesis of gangliosides
INVENTOR(S): DeFrees, Shawn, San Marcos, CA, United States
PATENT ASSIGNEE(S): Neose Technologies, Inc., Horsham, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6440703	B1	20020827
APPLICATION INFO.:	US 2001-935363		20010822 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-203200, filed on 30 Nov 1998, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-67693P	19971201 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Prats, Francisco	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Figure(s); 4 Drawing Page(s)	

LINE COUNT: 1312

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods for practical in vitro synthesis of gangliosides and other glycolipids. The synthetic methods typically involve enzymatic synthesis, or a combination of enzymatic and chemical synthesis. One or more of the enzymatic steps is preferably carried out in the presence of an organic solvent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 125 OF 164 USPATFULL on STN

ACCESSION NUMBER: 2001:63652 USPATFULL

TITLE: Method for enhancing the activity of an enzyme

INVENTOR(S): Hage, Ronald, Vlaardingen, Netherlands

Hora, Jiri, Den Haag, Netherlands

Swarthoff, Ton, Vlaardingen, Netherlands

Twisker, Robin Stefan, Vlaardingen, Netherlands

PATENT ASSIGNEE(S): Lever Brothers Company, division of Conopco, Inc., New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6225275	B1	20010501
APPLICATION INFO.:	US 1998-93635		19980604 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1997-201748	19970610
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Del Cotto, Gregory R.	
LEGAL REPRESENTATIVE:	Mitelman, Rimma	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	622	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A first aspect of the invention is a process for enhancing the activity of an oxidoreductase by adding to the enzyme, certain specific compounds which are capable of enhancing the activity of said oxidoreductase enzyme. A second aspect of the invention is an enzymatic bleach composition comprising an oxidoreductase and enhancing compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 128 OF 164 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN

ACCESSION NUMBER: 2001-578992 [65] WPIDS

DOC. NO. CPI: C2001-171892

TITLE: Assay for inorganic phosphate, involves treating sample with specific enzyme and correlating obtained detectable product with inorganic phosphate present in the reaction mixture.

DERWENT CLASS: B04 D16 E13

INVENTOR(S): HAUGLAND, R P; ZHOU, M

PATENT ASSIGNEE(S): (MOLE-N) MOLECULAR PROBES INC

COUNTRY COUNT: 2

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
US 6265179	B1	20010724	(200165)*		18
GB 2360846	A	20011003	(200166)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
-----------	------	-------------	------

US 6265179	B1	US 2000-495882	20000201
GB 2360846	A	GB 2001-2200	20010129

PRIORITY APPLN. INFO: US 2000-495882 20000201

AN 2001-578992 [65] WPIDS

AB US 6265179 B UPAB: 20011108

NOVELTY - Reaction mixture is produced by treating sample with phosphorylase enzyme (PE), PE substrate (PES), oxidase enzyme (OE), peroxidase enzyme (POE) and POE substrate (POES) of preset formula.

DETAILED DESCRIPTION - The method involves producing a reaction mixture by treating a sample, simultaneously or sequentially with a phosphorylase enzyme, phosphorylase enzyme substrate, oxidase enzyme, peroxidase enzyme and peroxidase enzyme substrate. When inorganic phosphate is present in the reaction mixture, phosphorylase enzyme converts inorganic phosphate and phosphorylase enzyme substrate into phosphorylase product(s), at least one of which is an oxidase substrate for oxidase enzyme, oxidase enzyme converts oxidase substrate into oxidase product(s) at least one of which is hydrogen peroxide, and peroxidase enzyme converts peroxidase enzyme substrate into a detectable product in presence of hydrogen peroxide. The presence or amount of detectable product in the reaction mixture is detected and correlated with presence or amount of inorganic phosphate in the reaction mixture. The peroxidase enzyme substrate is represented by formula (I).

R2-R5 = H, F, Cl, Br, I, CN, 1-6C alkyl or 1-6C alkoxy each optionally substituted by F, Cl, Br, I, carboxylic acid, its salt or its ester of 1-6C alcohol, sulfonic acid or its salt;

R1, R6 = H, or R1 in combination with R2 or R5 in combination with R6 or both form a fused aromatic six membered ring optionally substituted by one or more times of F, Cl, Br, I, CN, 1-18C alkyl or 1-18C alkoxy each optionally substituted by F, Cl, Br, I, carboxylic acid, its salt or its ester of 1-6C alcohol, sulfonic acid or its salt;

A, B' = OH or NR8R9;

R8, R9 = H, 1-6C alkyl, 1-6C carboxyalkyl or its salt, 1-6C sulfoalkyl or its salt, each optionally substituted by amino, hydroxy, carboxylic acid, its salt or its ester of 1-6C alcohol, or R8 in combination with R9 forms piperidine, morpholine, pyrrolidine or piperazine, each optionally substituted by methyl, carboxylic acid, its salt or its ester of 1-6C alkyl, sulfonic acid or its salt, or R8 in combination with R2, or R9 in combination with R3, or both form a 5- or 6-membered ring optionally substituted by one or more times F, Cl, Br, I, CN, 1-6C alkyl or 1-6C alkoxy each optionally substituted by F, Cl, Br, I, carboxylic acid, its salt or its ester of 1-6C alcohol, sulfonic acid or its salt;

X = N-(C=Y)-R10, N-(SO2)-R11 or CHR12;

Y = O or S;

R10 = H, 1-6C (perfluoro)alkyl, 1-6C alkoxy, 1-6C alkenyl, aryl, amino, 1-6C alkylamino or 1-6C dialkylamino;

R11 = H, 1-6C (perfluoro)alkyl, 1-6C alkenyl, aryl, amino, 1-6C alkylamino or 1-6C dialkylamino;

R12 = H, F, CN, carboxylic acid, its salt or its ester of 1-6C alcohol, or 1-6C alkyl optionally substituted one or more times by F, Cl, Br, carboxylic acid, its salt or its ester of 1-6C alcohol, sulfonic acid or its salt, amino, 1-6C alkylamino or 1-6C dialkylamino or compound (Ia);

R13-R17 = H, F, Cl, Br, I, sulfonic acid, its salt, carboxylic acid or its salt.

INDEPENDENT CLAIMS are also included for the following:

(i) Assay of maltose: The method involves producing a reaction mixture by treating a sample simultaneously or sequentially with inorganic phosphate, maltose phosphorylase enzyme, glucose oxidase enzyme, peroxidase enzyme, and peroxidase enzyme substrate. When maltose is present in reaction mixture, maltose phosphorylase converts inorganic phosphate and maltose into glucose and glucose-1-phosphate, glucose oxidase converts glucose into oxidase products, at least one of which is

H2O2, and peroxidase enzyme converts peroxidase enzyme substrate into a detectable product in presence of H2O2. The presence or amount of detectable product is detected and correlated with maltose in the reaction mixture;

(ii) Assay for phosphate-producing enzyme: The method involves producing reaction mixture by treating sample with appropriate substrate for phosphate-producing enzyme, phosphorylase enzyme, phosphorylase enzyme substrate, oxidase enzyme and peroxidase enzyme substrate. The phosphate-producing enzyme converts phosphate-producing enzyme substrate into product(s), at least one of which is inorganic phosphate, phosphorylase enzyme converts inorganic phosphate and phosphorylase enzyme substrate into phosphorylase product(s), at least one of which is oxidase substrate and oxidase enzyme converts oxidase substrate into oxidase product(s), at least one of which is hydrogen peroxide, and peroxidase enzyme converts peroxidase enzyme substrate into detectable compound. The presence or amount of detectable product is correlated with presence or amount of phosphate producing enzyme;

(iii) Composition comprising phosphorylase enzyme, phosphorylase enzyme substrate, oxidase enzyme, peroxidase enzyme and peroxidase enzyme substrate; and

(iv) Kit comprising phosphorylase enzyme, phosphorylase enzyme substrate, oxidase enzyme, peroxidase enzyme and peroxidase enzyme substrate.

USE - For detecting and quantifying inorganic phosphate in samples.

ADVANTAGE - The method is highly sensitive and may be utilized at wavelengths that are more compatible with biological samples. The method is performed at physiological pH and continuous assay is permitted. The method is valuable tool for measuring variety of phosphate dependent enzymes in biological samples.

Dwg.0/2

L5 ANSWER 129 OF 164 IFIPAT COPYRIGHT 2006 IFI on STN
AN 03540034 IFIPAT;IFIUDB;IFICDB
TITLE: METHOD OF SEQUENCING DNA BASED ON THE DETECTION OF
THE RELEASE OF **PYROPHOSPHATE** AND
ENZYMATIC NUCLEOTIDE DEGRADATION; USING
POLYMERASE CHAIN REACTION TO EXTEND A PRIMER AND
RELEASE **INORGANIC PYROPHOSPHATE**,
THEN DETECTING RELEASE OF **INORGANIC**
PHOSPHATE TO IDENTIFY BASE COMPLEMENTARY TO
TARGET POSITION; **REMOVING** UNINCORPORATED
NUCLEOTIDES USING **ENZYME**
INVENTOR(S): Nyren; Pal, Skarpnack, SE
PATENT ASSIGNEE(S): Pyrosequencing AB, Uppsala, SE
PRIMARY EXAMINER: Horlick, Kenneth R
AGENT: Baker Botts

	NUMBER	PK	DATE
PATENT INFORMATION:	US 6258568	B1	20010710
	(CITED IN 001 LATER PATENTS)		
	WO 9828440		19980702
APPLICATION INFORMATION:	US 1999-331517		19990723
	WO 1997-GB3518		19971222
			19990723 PCT 371 date
			19990723 PCT 102(e) date
EXPIRATION DATE:	22 Dec 2017		

	NUMBER	DATE
PRIORITY APPLN. INFO.:	GB 1996-26815	19961223
FAMILY INFORMATION:	US 6258568	20010710
DOCUMENT TYPE:	Utility	
	REASSIGNED	
FILE SEGMENT:	CHEMICAL	

GRANTED

MICROFILM REEL NO: 010241 FRAME NO: 0503

NUMBER OF CLAIMS: 17

GRAPHICS INFORMATION: 6 Drawing Sheet(s), 6 Figure(s).

AB The present invention relates to a method of sequencing DNA, based on the detection of base incorporation by the release of pyrophosphate (PPi) and simultaneous enzymatic nucleotide degradation.

CLMN 17

GI 6 Drawing Sheet(s), 6 Figure(s).

L5 ANSWER 135 OF 164 USPATFULL on STN

ACCESSION NUMBER: 1999:78582 USPATFULL

TITLE: Enzymatic synthesis of glycosidic linkages

INVENTOR(S): Defrees, Shawn, San Marcos, CA, United States

Bayer, Robert J., San Diego, CA, United States


Ratcliffe, Murray, Carlsbad, CA, United States

PATENT ASSIGNEE(S): Cytel Corporation, San Diego, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5922577		19990713
APPLICATION INFO.:	US 1996-628545		19960410 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-419669, filed on 11 Apr 1995, now patented, Pat. No. US 5728554 And Ser. No. US 1995-419659, filed on 11 Apr 1995		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Prats, Francisco		
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP		
NUMBER OF CLAIMS:	35		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Figure(s); 10 Drawing Page(s)		
LINE COUNT:	1809		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides improved methods for the formation of glycosidic linkages. These methods are useful for the preparation of compounds of formula:



CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d kwic 4 8 12 17 24 30-31 56-57 62 65 66 71-72 96 111 125 128 129 135 15

L5 ANSWER 4 OF 164 USPATFULL on STN

DETD . . . being added almost daily to maintain the metal ion concentration. Manganese ion is a required cofactor for at least one enzyme in the sialyl transferase cycle. However, the manganese ion inorganic phosphate produced form a complex of very low solubility. Because of this limited solubility, the transferase cycle can continue to proceed, but at reduced reaction rates. By supplementing the manganese ions which are lost by precipitation with pyrophosphate, the rate of reaction can be maintained. Thus, when manganese ion concentration is maintained in an optimal range, the sialyl. . .

L5 ANSWER 8 OF 164 USPATFULL on STN

DETD Thus, the multi-enzyme system started with mannose 1-phosphate (Man-1-P) which was synthesized from mannose in three steps in this laboratory [Sim et al., J. Am. Chem. Soc., in press]. Mannose 1-phosphate reacted with GTP catalyzed by GDP-mannose